Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis

BACKGROUND: Research on JAK family members as therapeutic targets for autoimmune diseases has brought tofacitinib and baricitinib into clinical for the treatment of rheumatoid arthritis and other autoimmune diseases. Despite the potent efficacy of these first-generation JAK inhibitors, their broad-s...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Inflamm Res
Asıl Yazarlar: Zhang, Ning, Zhang, Changqing, Zeng, Zhihong, Zhang, Jiyong, Du, Shengnan, Bao, Chunde, Wang, Zhe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove 2021
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8153205/
https://ncbi.nlm.nih.gov/pubmed/34054304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JIR.S301076
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller